The authors lay out prominent and pressing threats to public and planet health, though the reader needs to wait until the end to find out what can be done to save our planet and the people who live on ...

While not a comprehensive review of the pandemic, this book can provide a useful roadmap for the next serious Administration’s public health leaders who seek to get ahead of impending pandemic threats ...

How states implement new Medicaid cost-sharing rules created by the OBBBA will have significant impact on program efficiency and enrollee health.

There is an alternative to the One Big Beautiful Bill’s approach of kicking millions of people off their health care and ...

Precision medicine has transformed diagnosis and treatment, yet prevention often remains anchored in assumptions that no longer reflect how risk is acquired across the life-course.

Health Affairs' Rob Lott interviews Dr. Robert Wachter, Professor and Chair of the Department of Medicine at UCSF, about his ...

As the Japanese population has aged rapidly, Japan’s experience has implications for other high-income countries, including the United States. The aging of Japan’s population, coupled with the ...

Young adults’ access to contraception is shifting after the June 2022 United States Supreme Court Dobbs v. Jackson Women’s Health Organization decision. This concurrent mixed-methods study measured ...

Accelerated approval can serve patients well—but only when surrogate endpoints are reliable and clearly predict outcomes that matter to patients.

Transparency Scorecard to increase visibility into non-clinical dimensions of MA plan performance that fall outside the appropriate scope of Star Ratings.

Daniel R. Arnold ([email protected]), Brown University, Providence, Rhode Island. Brent D. Fulton, University of California Berkeley, Berkeley, California. During the past several decades, physicians ...

The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...